Crinetics Pharmaceuticals, Inc.·4

Dec 18, 6:54 PM ET

Struthers Richard Scott 4

4 · Crinetics Pharmaceuticals, Inc. · Filed Dec 18, 2025

Insider Transaction Report

Form 4
Period: 2025-12-18
Struthers Richard Scott
DirectorPresident & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-18$9.28/sh+16,342$151,654336,359 total
  • Exercise/Conversion

    Common Stock

    2025-12-18$15.29/sh+28,400$434,236364,759 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-12-1816,3420 total
    Exercise: $9.28Exp: 2028-05-24Common Stock (16,342 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-12-1828,400259,058 total
    Exercise: $15.29Exp: 2031-02-26Common Stock (28,400 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    661,205
  • Common Stock

    (indirect: By Trust)
    106,000
  • Common Stock

    (indirect: By Trust)
    110,000
  • Common Stock

    (indirect: By Trust)
    100,000
  • Common Stock

    (indirect: By Spouse)
    1,000
Footnotes (2)
  • [F1]1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
  • [F2]1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Documents

1 file
  • 4
    wk-form4_1766102083.xmlPrimary

    FORM 4